Literature DB >> 21917870

Depression in primary hyperparathyroidism: prevalence and benefit of surgery.

Rachel P Espiritu1, Ann E Kearns, Kristin S Vickers, Clive Grant, Euijung Ryu, Robert A Wermers.   

Abstract

CONTEXT: Patients with primary hyperparathyroidism (PHP) often report nonspecific symptoms including mood disturbances.
OBJECTIVE: The objective of the study was to determine the frequency of depression in PHP and assess its response to parathyroidectomy.
METHODS: A case-control study at a referral center in Rochester, MN, performed Patient Health Questionnaire-9 (PHQ-9) assessments in observed (n = 81) and surgical (n = 88) PHP and benign nontoxic surgical thyroid disease (n = 85) at baseline and 1, 3, 6, and 12 months after surgery or the initial questionnaire in observed PHP. Baseline PHQ-9 scores and their response to surgery were evaluated.
RESULTS: The groups were similar in gender and depression history, but PHP patients were older. Baseline PHQ-9 scores were 1.71 points higher in PHP than controls after adjusting for age and gender (P = .004). Clinically significant PHQ-9 scores (≥10) were twice as common in PHP (31.4%) compared with thyroid subjects (15.3%). Parathyroidectomy resulted in significant and sustained reductions in PHQ-9 scores, which were greater than observed PHP at all time points (P < .001). PHP patients with clinically significant PHQ-9 scores dropped to 7.4% (P < .001) and 7.6% (P < .001) at 1 month and 1 yr after parathyroidectomy. There were greater declines in PHQ-9 scores after parathyroidectomy at 1, 3, and 6 months (P < .001) and 1 yr (P = .061) compared with thyroid surgery.
CONCLUSIONS: Depression is common in patients with PHP. Parathyroidectomy results in greater improvement in PHQ-9 scores compared with thyroid surgery or observation of PHP.

Entities:  

Mesh:

Year:  2011        PMID: 21917870     DOI: 10.1210/jc.2011-1486

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

2.  Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure.

Authors:  Raul R Blanco; Harland Austin; Richard N Vest; Ravinder Valadri; Wei Li; Bernard Lassegue; Qing Song; Barry London; Samuel C Dudley; Heather L Bloom; Charles D Searles; A Maziar Zafari
Journal:  J Card Fail       Date:  2012-08-09       Impact factor: 5.712

3.  TNF-α alters the release and transfer of microparticle-encapsulated miRNAs from endothelial cells.

Authors:  Tamas Alexy; Kimberly Rooney; Martina Weber; Warren D Gray; Charles D Searles
Journal:  Physiol Genomics       Date:  2014-10-14       Impact factor: 3.107

4.  Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Authors:  T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz
Journal:  Langenbecks Arch Surg       Date:  2021-04-21       Impact factor: 3.445

Review 5.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

6.  Contemporary surgical treatment of primary hyperparathyroidism without intraoperative parathyroid hormone measurement.

Authors:  O A Mownah; G Pafitanis; W M Drake; J N Crinnion
Journal:  Ann R Coll Surg Engl       Date:  2015-11       Impact factor: 1.891

7.  Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms.

Authors:  A Trombetti; E R Christ; C Henzen; G Gold; M Brändle; F R Herrmann; C Torriani; F Triponez; M Kraenzlin; R Rizzoli; C Meier
Journal:  J Endocrinol Invest       Date:  2016-01-07       Impact factor: 4.256

Review 8.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 9.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

10.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.